The highest affinity ghrelin-based analogue for fluorine-18
positron
emission tomography, [Inp1,Dpr3(6-FN),1Nal4,Thr8]ghrelin(1–8) amide (1), has remarkable subnanomolar receptor affinity (IC50 = 0.11 nM) toward the growth hormone secretagogue receptor 1a (GHSR).
However, initial in vivo PET imaging and biodistribution
of [18F]1 in mice demonstrated an unfavorable
pharmacokinetic profile with rapid clearance and accumulation in liver
and intestinal tissue, prompting concerns about the metabolic stability
of this probe. The aims of the present study were to examine the proteolytic
stability of ghrelin analogue 1 in the presence of blood
and liver enzymes, structurally modify the peptide to improve stability
without impeding the strong binding affinity, and measure the presently
unknown functional activity of ghrelin(1–8) analogues. The in vitro stability and metabolite formation of 1 in human serum and liver S9 fraction revealed a metabolic soft spot
between amino acids Leu5 and Ser6 in the peptide
sequence. A focused library of ghrelin(1–8) analogues was synthesized
and evaluated in a structure–activity–stability relationship
study to further understand the structural importance of the residues
at these positions in the context of stability and receptor affinity.
The critical nature of l-stereochemistry at position 5 was
identified and substitution of Ser6 with l-2,3-diaminopropionic
acid led to a novel ligand with substantially improved in
vitro stability while maintaining subnanomolar GHSR affinity.
Despite the highly modified nature of these analogues compared to
human ghrelin, ghrelin(1–8) analogues were found to recruit
all G protein subtypes (Gαq/11/13/i1/oB) known to
associate with GHSR as well as β-arrestins with low micromolar
to nanomolar potencies. The study of these analogues demonstrates
the ability to balance desirable ligand properties, including affinity,
stability, and potency to produce well-rounded candidate molecules
for further in vivo evaluation.